Head of the Division of Cancer Therapeutics and Director of the Cancer Therapeutics Unit

Ref: 5474

The Institute of Cancer Research

London

Apply Now

Role Managed by:

Alex Hurlow

Research Associate

t: +44 (0)20 7340 6282

e: alex.hurlow@perrettlaver.com

Primary Practice Group: Higher Education and Research

Salary & Benefits: Competitive

Closing Date: 24/01/2022

Formal Interview Date: April 2022

The Institute of Cancer Research, London, is one of the world’s most influential cancer research institutes with an outstanding track record of achievement dating back more than 100 years. Our mission is to make the discoveries that defeat cancer, which we seek to achieve through world-leading research and internationally excellent learning and teaching.

Today, The Institute of Cancer Research (ICR) is rated as the UK’s leading higher education institution for the quality and impact of our research. We are world leaders in the identification of cancer-related genes, discovery of new targeted cancer drugs and development of new forms of high-precision radiotherapy. Our unique partnership with The Royal Marsden NHS Foundation Trust and integrated 'bench to bedside and back again’ approach ensure our research advances rapidly reach patients and place us among the top four centres in the world for cancer research and treatment.

The Division of Cancer Therapeutics has an unrivalled track record at discovering novel cancer treatments for the personalised treatment of cancer. The Division houses the Cancer Therapeutics Unit (CTU) as one of the largest academic cancer drug discovery groups in the world. With our collaborators, CTU has discovered 20 preclinical development candidates since 2005, 11 of which have been progressed to clinical evaluation. Our drug abiraterone (Zytiga) has been approved in the US, Canada, and Europe for late-stage prostate cancer.

The ICR is now seeking a leading cancer biologist/medicinal chemist of international standing and experience to head the Division of Cancer Therapeutics and lead the CTU as its Director. Reporting to the CEO, the appointee will provide strategic vision and scientific leadership to the Division and the CTU. They will run a personal research group in a relevant area participating in multi-disciplinary drug discovery within the CTU and will provide leadership, development, evaluation and governance of the research conducted within the Division such that an intellectual environment is created furthering the international excellence of the ICR’s research in line with its agreed scientific strategy.  

The successful candidate will demonstrate excellence in cancer biology and/or medicinal chemistry coupled with broad experience of current drug discovery, particularly across the target identification to drug candidate phases. Applicants will have either extensive commercial experience of successful drug discovery and development, scientific leadership and portfolio management in biotech/pharma; or have an exceptionally strong academic track record in cancer biology and small molecule drug discovery; or will have a combination of both backgrounds. The appointee will demonstrate a strong desire to discover innovative drugs for cancer patients and will be an excellent communicator who inspires others with a clear vision for the future of cancer drug discovery at the ICR

The ICR has engaged Perrett Laver to support the Appointment Panel for this role. For informal enquiries about the role please contact Dr Alex Hurlow at alex.hurlow@perrettlaver.com or +44 (0)20 7340 6282.

The closing date for applications is at 9am (GMT) on Monday 24th January 2022. Final stage interviews will take place in April 2022.

Accessibility

For a conversation in confidence, please contact Dr Alex Hurlow on +44 (0)20 7340 6282 or by sending an email to Alex.Hurlow@perrettlaver.com

Should you require access to these documents in alternative formats, please contact Lina Franzen on lina.franzen@perrettlaver.com

If you have comments that would support us to improve access to documentation, or our application processes more generally, please do not hesitate to contact us via accessibility@perrettlaver.com

Data Protection and Privacy

Protecting your personal data is of the utmost importance to Perrett Laver and we take this responsibility very seriously. Any information obtained by our trading divisions is held and processed in accordance with the relevant data protection legislation. The data you provide us with is securely stored on our computerised database and transferred to our clients for the purposes of presenting you as a candidate and/or considering your suitability for a role you have registered interest in.

As defined under the General Data Protection Regulation (GDPR) Perrett Laver is a Data Controller and a Data Processor, and our legal basis for processing your personal data is ‘Legitimate Interests’. You have the right to object to us processing your data in this way. For more information about this, your rights, and our approach to Data Protection and  Privacy, please visit our website:  www.perrettlaver.com/information/privacy